Boehringer-Ingelheim
Guardant Health, Boehringer Ingelheim Partner on Companion Diagnostic for New Lung Cancer Drug
The companies aim to establish Guardant360 CDx as a tool to identify patients with HER2 mutations eligible for treatment with the targeted drug zongertinib.
Notable Labs Cleared by FDA to Begin Phase II Trial of Volasertib in AML
The firm will use its Predictive Medicine Platform to identify patients most likely to respond to volasertib in the study.
Notable Labs to Study Volasertib in Phase II AML Trial
The firm will use its functional medicine platform to identify AML patients most likely to respond to treatment with volasertib in a Phase II trial.
Boehringer Ingelheim, CBmed Partner to Advance Biomarker-Informed Oncology Drugs
The partnership will identify and validate biomarkers for new indications and enable patient selection for Boehringer Ingelheim's oncology therapies.
CMS Makes First Price Offers Under IRA Medicare Drug Price Negotiations Program
The drugmakers subjected to the first round of negotiations, many of which also market precision oncology drugs, have been staunchly opposed to the law.